Rabussay
Dietmar Rabussay, Solana Beach, CA US
Patent application number | Description | Published |
---|---|---|
20110009807 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD - This invention comprises an improved electroporation electrode system comprising a single needle and a ring or donut shaped electrode wherein the difference in surface area of the electrodes provide for a substantial reduction of current density near the surface of the treated tissue and a more concentrated current density sufficient for electroporation only in tissues adjacent to the terminal portion of the single needle electrode. Thus, this invention provides for targeting specific tissue for electroporation and also should provide for lessening the sensation of electric current in the treated tissue. | 01-13-2011 |
20120143120 | METHOD AND DEVICE FOR TREATING MICROSCOPIC TUMORS REMAINING IN TISSUES FOLLOWING SURGICAL RESECTION - This invention concerns treating apparently normal tissue surrounding sites of cancerous tumors so as to reduce both the probability of a recurrence of cancer at and near the site of a cancerous tissue, and to reduce the amount of apparently healthy tissue that is usually excised along with the tumor, thereby providing a substantial benefit to the cancer patient by eliminating or delaying tumor recurrence and sparing normal tissue for its functionality and for avoiding unnecessary disfigurement. | 06-07-2012 |
Dietmar P. Rabussay, San Diago, CA US
Patent application number | Description | Published |
---|---|---|
20080215032 | Minimizing Metal Toxicity During Electroporation Enhanced Delivery of Polynucleotides - Methods are provided for introducing a polynucleotide into healthy tissue and generating a pulsed electric field in the tissue via invasive electrodes, resulting in enhanced delivery of the polynucleotide into cells of the tissue, while minimizing local side effects to the electroporated tissue and systemic side effects to the electroporated organism due to metal contaminants released from said electrodes. In one embodiment, the invention methods Use electrodes of gold, gold alloys, or other metal that minimize the introduction of toxic amounts of the metal into electroporated tissue. In other embodiments, the invention methods are utilized for the gene therapy by administering DNA to cells of suitable target tissue, and for the induction of an immune response by administration of a DNA vaccine. | 09-04-2008 |
Dietmar Paul Rabussay, Solana Beach, CA US
Patent application number | Description | Published |
---|---|---|
20100249488 | METHOD OF CONTACTLESS MAGNETIC ELECTROPORATION - This invention provides a novel method of tissue electroporation that eliminates the need for electrodes that conduct electricity to the tissues. This invention creates electric currents and fields sufficient for porating cell membranes for improving the delivery of polynucleotides such as plasmid and linear DNA and RNA constructs, and polypeptides such as antigen protein constructs into mammalian eucaryotic cells purely by magnetic field pulses that does not require the use of contacting electrodes to conduct electric or ionic current. This invention thus provides a method for improving transfection and immunogenicity of pharmaceutical substances without direct contact with a living body, and may be called magnetopermeabilization. A concomitant aspect of the invention is the method by which a drug such as a solution containing DNA is delivered to a targeted tissue bed that is optimal in conjunction with magnetopermeabilization for maximal transgene expression and drug effect. | 09-30-2010 |
20100285040 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting - Disclosed are methods of enhancing immune responses. Such methods involve the administration of vaccine compositions to different tissues to elicit an enhanced immune response. The enhanced response arises from the vaccination and boosting route of administration in two separate patient tissues, for example, by first administering a priming vaccination into skin and later administering a boost vaccination in muscle. In each case, priming and boosting, the administration of the vaccine composition is preferably carried out using contemporaneous electroporation-assisted delivery of the antigenic agent. | 11-11-2010 |